Application of labeling reagent of long-chain fatty acid coenzyme A ligase 1 in preeclampsia diagnosis or prediction

A long-chain fatty acid, medium-long-chain fatty acid technology, applied in the field of biomedicine, can solve the problems of false positives or false negatives, instability, and the prediction performance of markers is not obvious, and achieves easy operation, accurate results, and large-scale promotion. The effect of applying value

Pending Publication Date: 2020-02-14
中国人民武装警察部队特色医学中心
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For this goal, there have been a lot of PE prediction research and verification work, mainly to find new serum biomarkers and establish prediction models for early prediction. Methods
Even if there are a few potential markers (such as sFlt-1 / PlGF ratio), they are only valuable in prolonging expectant treatment in the third trimester, and cannot be used to predict the occurrence of PE; some markers have insignificant or unstable predictive performance, Cannot be used clinically
Some studies have used the combination of maternal risk factors, blood pressure, PlGF and uterine artery Doppler to predict preterm preeclampsia (<37 weeks), but its effectiveness has high false positive or false negative results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of labeling reagent of long-chain fatty acid coenzyme A ligase 1 in preeclampsia diagnosis or prediction
  • Application of labeling reagent of long-chain fatty acid coenzyme A ligase 1 in preeclampsia diagnosis or prediction
  • Application of labeling reagent of long-chain fatty acid coenzyme A ligase 1 in preeclampsia diagnosis or prediction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Long-chain fatty acid coenzyme A ligase 1 as a screening marker for early warning and diagnosis of hypertensive disorders in pregnancy

[0037] Paired samples: 30 cases of placental tissue from preeclampsia; 30 cases of normal placental tissue; during the case collection process, placental tissue samples were collected from approximately the same age and gestational weeks, and metabolic diseases such as diabetes, obesity, and hyperlipidemia were excluded pregnant woman. Clinical trials are human research methods approved by a medical ethics committee. All operations complied with relevant ethical guidelines.

[0038] Weigh 0.3 g of each placental tissue, remove the residual blood with normal saline, place it in liquid nitrogen tissue for quick freezing, place it in a mortar filled with liquid nitrogen, and grind it into powder. Add 400 μL of protein lysate, perform ultrasonic lysis under ice bath conditions, power 300W, work for 1s, rest for 5s, 50 cycles. ...

Embodiment 2

[0040] Example 2 The level difference of ACSL1 in the placenta tissue of patients with preeclampsia and the placenta tissue of normal women

[0041] Paired samples: 30 cases of placental tissue from preeclamptic women; 30 cases of normal maternal placental tissue;

[0042] All patients were volunteers who gave informed consent.

[0043] Each sample was taken separately for immunohistochemical detection. The primary antibody used was rabbit anti-ACSL1 antibody from Abcam Company, Cat. No. Ab76702. The immunohistochemistry kit used SP Rabbit & MouseHRP Kit Rabbit / Mouse Universal Streptavidin-HRP kit from Kangwei Century Biotechnology Co., Ltd., catalog number CW0120A. DAB color reaction was used. The results of the placental tissue of a patient with preeclampsia and the placental tissue of a normal woman are shown in figure 2 (100x magnification). Image-Pro Plus 6.0 software was used to scan and analyze the optical density value of the placental tissues of preeclampsia and...

Embodiment 3

[0045] Example 3 Differences in the level of ACSL1 in the serum of different populations

[0046] Two populations: 30 cases of preeclampsia; 30 cases of normal parturients; all volunteers with informed consent.

[0047] The serum of 30 normal pregnant women and 30 pregnant women with preeclampsia were collected, and 200 μL was taken for each case. After centrifugation at 3500 rpm for 10 min at 4°C, the supernatant was taken for testing. The Abbexa company ACSL1 ELISA kit, catalog number abx110794, was used.

[0048] Perform follow-up operations according to the instructions of the kit: add 100 μL serum supernatant to the 96-well plate, add 100 μL reagent 1 to the blank well, and add 100 μL ACSL1 standard solution with a concentration of 20 μM to the standard well. Add 100 μL of reagent two and 25 μL of reagent three to all wells. After mixing, let stand for 5min.

[0049] Use a microplate reader to detect the absorbance value of each well at a wavelength of 405 nm, and cal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention, which belongs to the biomedicine field, discloses application of a labeling reagent of long-chain fatty acid coenzyme A ligase 1 in preparation of a kit for diagnosing whether a pregnant woman suffers from preeclampsia or predicting whether a pregnant woman has the risk of suffering from preeclampsia. The invention further discloses a kit for diagnosing whether a pregnant woman suffers from preeclampsia or predicting whether the pregnant woman has the risk of suffering from preeclampsia or not. The kit comprises a labeling reagent of the long-chain fatty acid coenzyme A ligase 1. Therefore, a novel biomarker for diagnosis and early warning of the preeclampsia of hypertensive disorder complicating pregnancy and has the important clinical value.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of long-chain fatty acid coenzyme A ligase 1 in diagnosing or predicting preeclampsia. Background technique [0002] Preeclampsia (preeclampsia, PE) is an important subtype of hypertensive disorders of pregnancy, accounting for more than half of hypertensive disorders of pregnancy, and is one of the leading causes of maternal mortality worldwide. The etiology and pathogenesis of PE have not been fully elucidated so far. Current research shows that PE is a placental-derived disease with multiple factors and mechanisms acting together, and has a similar pathology to cardiovascular disease (CVD) Physiological mechanisms, such as oxidative stress, vascular endothelial damage, insulin resistance, lipid metabolism disorders, etc. PE not only leads to adverse events in pregnancy, threatens the lives of mother and child, but also is a risk factor for long-term CVD ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/573
CPCG01N33/573G01N2800/368G01N2333/9015
Inventor 蔡伟徐忠伟牛秀珑陈少伯李玉明
Owner 中国人民武装警察部队特色医学中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap